Cytokinetics, Inc. (CYTK)
61.95
-1.97
(-3.08%)
USD |
NASDAQ |
Oct 16, 16:00
61.97
+0.02
(+0.03%)
After-Hours: 20:00
Cytokinetics Cash from Investing (Quarterly) : -507.00M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -507.00M |
| March 31, 2026 | 145.49M |
| December 31, 2025 | -71.19M |
| September 30, 2025 | -70.98M |
| June 30, 2025 | 52.88M |
| March 31, 2025 | 105.96M |
| December 31, 2024 | 110.86M |
| September 30, 2024 | -45.05M |
| June 30, 2024 | -651.55M |
| March 31, 2024 | 32.64M |
| December 31, 2023 | -81.41M |
| September 30, 2023 | 73.04M |
| June 30, 2023 | 82.13M |
| March 31, 2023 | 165.50M |
| December 31, 2022 | 29.25M |
| September 30, 2022 | -292.37M |
| June 30, 2022 | 65.27M |
| March 31, 2022 | -64.28M |
| December 31, 2021 | 47.34M |
| September 30, 2021 | -208.72M |
| June 30, 2021 | 18.88M |
| March 31, 2021 | -5.276M |
| December 31, 2020 | -173.62M |
| September 30, 2020 | -101.02M |
| June 30, 2020 | 34.64M |
| Date | Value |
|---|---|
| March 31, 2020 | 43.49M |
| December 31, 2019 | -105.27M |
| September 30, 2019 | 13.68M |
| June 30, 2019 | -2.767M |
| March 31, 2019 | 19.64M |
| December 31, 2018 | 26.51M |
| September 30, 2018 | 2.677M |
| June 30, 2018 | -44.19M |
| March 31, 2018 | 20.14M |
| December 31, 2017 | 30.76M |
| September 30, 2017 | 39.66M |
| June 30, 2017 | -23.95M |
| March 31, 2017 | -112.30M |
| December 31, 2016 | -41.97M |
| September 30, 2016 | 13.97M |
| June 30, 2016 | -3.916M |
| March 31, 2016 | -20.16M |
| December 31, 2015 | 25.41M |
| September 30, 2015 | 11.31M |
| June 30, 2015 | 11.44M |
| March 31, 2015 | -32.09M |
| December 31, 2014 | 6.304M |
| September 30, 2014 | 10.07M |
| June 30, 2014 | 8.44M |
| March 31, 2014 | -28.86M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | -1.614B |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| BioMarin Pharmaceutical, Inc. | -5.102B |
| Exelixis, Inc. | 91.43M |
| Ionis Pharmaceuticals, Inc. | 23.50M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -159.84M |
| Cash from Financing (Quarterly) | 792.86M |
| Free Cash Flow | -580.72M |
| Free Cash Flow Per Share (Quarterly) | -1.243 |
| Free Cash Flow to Equity (Quarterly) | -146.01M |
| Free Cash Flow to Firm (Quarterly) | -129.34M |
| Free Cash Flow Yield | -7.53% |